Sangamo Therapeutics Inc (SGMO) Com Stk USD0.01
Sell:$0.60Buy:$0.61
$0.05
(9.57%)
- This stock can be held in a
Stocks and Shares ISA$0.05
(9.57%)$0.05
(9.57%)Company Information
About this company
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
Key people
Key facts
- EPICSGMO
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS8006771062
- Market cap$114.00m
- Employees183
- Shares in issue237.60m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.